Johnson & Johnson

Legal News Roundup – June 10

Here's a roundup of some major legal stories from the past week. Big Fines for Robocalls Reuters - The Federal Communications Commission  (FCC) proposed a record-setting $225 million fine against Texas-based health insurance telemarketers for allegedly placing 1 billion illegal robocalls. John C. Spiller II, Jakob Mears and their respective companies were named in...

read more

Jury awards $72M in J & J baby powder case

On Feb 22, a jury in Missouri awarded $72 million in damages to the family of Jacqueline Fox, a woman who died of ovarian cancer after using Johnson’s Baby Powder for genital hygiene for decades. Fox was just one of thousands of women from across the country who filed claims against Johnson & Johnson for failing...

read more

J & J faces thousands of Risperdal lawsuits

More than 5,000 lawsuits have been filed against Johnson & Johnson for failure to warn doctors and consumers that Risperdal can cause boys to grow large breasts, a condition known as gynecomastia. Risperdal Litigation At least 1,500 Risperdal cases have been consolidated in Pennsylvania on behalf of individuals who allege the drug caused excessive male breast...

read more

Whistleblowers Receive $168 Million

In one of the largest payouts in history, people from three states will be taking home a share of the $167.7 million awarded to whistleblowers for exposing Johnson & Johnson’s use of improper marketing and kickbacks. $2 Billion Settlement In a press conference yesterday, Attorney General Eric Holder told reporters that Johnson & Johnson...

read more

Ohio Drug Company Closure Sparks Fear of Cancer Drug Shortage

The chemotherapy drug Doxil may soon be in short supply. That’s bad news for women battling ovarian cancer, patients with cancer of the blood, and those suffering from AIDS-related Kaposi’s sarcoma. Ben Venue Laboratories Inc., the sole manufacturer of Johnson & Johnson’s cancer drug Doxil, announced they will be shutting their doors by the...

read more